Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This research will study safety and the body's immune (defense system) responses, including
anti-H5 flu antibodies (the body's protective proteins found in the blood), to an inactivated
influenza "H5" bird flu, virus vaccine. Participants will be assigned by chance to receive
the vaccine injections with and without an adjuvant, (substance that can improve vaccine
effectiveness so less vaccine may be used) MF59, or placebo (inactive substance). Five
different vaccine dose strengths will be evaluated. About 735 healthy participants, ages
18-49 will be asked to take part in this study. Study procedures include physical exam, blood
sampling, and use of a memory aid. Volunteers will participate for up to 13 months.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)